Clinical management of epithelial ovarian cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Ovarian cancer has high morbidity and mortality worldwide, and its mortality is the highest among female genital cancers. Improvement in clinical outcome is an urgent issue for ovarian cancer, and clinical management including treatment has been repeatedly studied. Tumor markers such as CA125, CA19-9, and HE4 and image diagnosis using MRI, CT, PET, etc. are indispensable diagnostic aid tools. In the initial treatment, primary debulking surgery (PDS) is basically effective, but fertility preservation can be considered depending on the case. For advanced cancers, interval debulking surgery (IDS) is considered after several cycles of neoadjuvant chemotherapy (NAC). Although the combination of paclitaxel and carboplatin (TC) regimen was originally established as the standard chemotherapy for ovarian cancer regardless of tissue type, new treatments in clinical trials, including molecular-targeted therapeutic agents, are being investigated. The main treatment for recurrent cancer is chemotherapy, and sensitivity to chemotherapy based on the disease-free interval has been considered in the choice of treatment. Furthermore, in recent years, risk-reducing bilateral salpingo-oophorectomy has been undertaken to prevent the onset of hereditary breast and ovarian cancer. It is also being studied how to manage the follow-up after treatment and hormone replacement.

Original languageEnglish
Title of host publicationCell Biology of the Ovary
Subtitle of host publicationStem Cells, Development, Cancer, and Clinical Aspects
PublisherSpringer Singapore
Pages135-151
Number of pages17
ISBN (Electronic)9789811079412
ISBN (Print)9789811079405
DOIs
Publication statusPublished - 2018 Jun 12

Fingerprint

Ovarian Neoplasms
Drug Therapy
Therapeutics
Fertility Preservation
Neoplasms
Mortality
Carboplatin
Ovariectomy
Tumor Biomarkers
Paclitaxel
Ovarian epithelial cancer
Clinical Trials
Hormones
Breast Neoplasms
Morbidity

Keywords

  • Adjuvant chemotherapy
  • Diagnostic imaging
  • Follow-up after treatment
  • Hormone replacement therapy
  • Interval debulking surgery
  • Molecular-targeted drugs
  • Neoadjuvant chemotherapy
  • Primary debulking surgery
  • Risk-reducing salpingo-oophorectomy
  • Staging laparotomy
  • Tumor marker

ASJC Scopus subject areas

  • Medicine(all)
  • Health Professions(all)

Cite this

Kobayashi, Y., Nomura, H., Kataoka, F., Tominaga, E., Banno, K., & Aoki, D. (2018). Clinical management of epithelial ovarian cancer. In Cell Biology of the Ovary: Stem Cells, Development, Cancer, and Clinical Aspects (pp. 135-151). Springer Singapore. https://doi.org/10.1007/978-981-10-7941-2_11

Clinical management of epithelial ovarian cancer. / Kobayashi, Yusuke; Nomura, Hiroyuki; Kataoka, Fumio; Tominaga, Eiichirou; Banno, Kouji; Aoki, Daisuke.

Cell Biology of the Ovary: Stem Cells, Development, Cancer, and Clinical Aspects. Springer Singapore, 2018. p. 135-151.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kobayashi, Y, Nomura, H, Kataoka, F, Tominaga, E, Banno, K & Aoki, D 2018, Clinical management of epithelial ovarian cancer. in Cell Biology of the Ovary: Stem Cells, Development, Cancer, and Clinical Aspects. Springer Singapore, pp. 135-151. https://doi.org/10.1007/978-981-10-7941-2_11
Kobayashi Y, Nomura H, Kataoka F, Tominaga E, Banno K, Aoki D. Clinical management of epithelial ovarian cancer. In Cell Biology of the Ovary: Stem Cells, Development, Cancer, and Clinical Aspects. Springer Singapore. 2018. p. 135-151 https://doi.org/10.1007/978-981-10-7941-2_11
Kobayashi, Yusuke ; Nomura, Hiroyuki ; Kataoka, Fumio ; Tominaga, Eiichirou ; Banno, Kouji ; Aoki, Daisuke. / Clinical management of epithelial ovarian cancer. Cell Biology of the Ovary: Stem Cells, Development, Cancer, and Clinical Aspects. Springer Singapore, 2018. pp. 135-151
@inbook{b2025a18f586405aa25a1793ba8d79a5,
title = "Clinical management of epithelial ovarian cancer",
abstract = "Ovarian cancer has high morbidity and mortality worldwide, and its mortality is the highest among female genital cancers. Improvement in clinical outcome is an urgent issue for ovarian cancer, and clinical management including treatment has been repeatedly studied. Tumor markers such as CA125, CA19-9, and HE4 and image diagnosis using MRI, CT, PET, etc. are indispensable diagnostic aid tools. In the initial treatment, primary debulking surgery (PDS) is basically effective, but fertility preservation can be considered depending on the case. For advanced cancers, interval debulking surgery (IDS) is considered after several cycles of neoadjuvant chemotherapy (NAC). Although the combination of paclitaxel and carboplatin (TC) regimen was originally established as the standard chemotherapy for ovarian cancer regardless of tissue type, new treatments in clinical trials, including molecular-targeted therapeutic agents, are being investigated. The main treatment for recurrent cancer is chemotherapy, and sensitivity to chemotherapy based on the disease-free interval has been considered in the choice of treatment. Furthermore, in recent years, risk-reducing bilateral salpingo-oophorectomy has been undertaken to prevent the onset of hereditary breast and ovarian cancer. It is also being studied how to manage the follow-up after treatment and hormone replacement.",
keywords = "Adjuvant chemotherapy, Diagnostic imaging, Follow-up after treatment, Hormone replacement therapy, Interval debulking surgery, Molecular-targeted drugs, Neoadjuvant chemotherapy, Primary debulking surgery, Risk-reducing salpingo-oophorectomy, Staging laparotomy, Tumor marker",
author = "Yusuke Kobayashi and Hiroyuki Nomura and Fumio Kataoka and Eiichirou Tominaga and Kouji Banno and Daisuke Aoki",
year = "2018",
month = "6",
day = "12",
doi = "10.1007/978-981-10-7941-2_11",
language = "English",
isbn = "9789811079405",
pages = "135--151",
booktitle = "Cell Biology of the Ovary",
publisher = "Springer Singapore",

}

TY - CHAP

T1 - Clinical management of epithelial ovarian cancer

AU - Kobayashi, Yusuke

AU - Nomura, Hiroyuki

AU - Kataoka, Fumio

AU - Tominaga, Eiichirou

AU - Banno, Kouji

AU - Aoki, Daisuke

PY - 2018/6/12

Y1 - 2018/6/12

N2 - Ovarian cancer has high morbidity and mortality worldwide, and its mortality is the highest among female genital cancers. Improvement in clinical outcome is an urgent issue for ovarian cancer, and clinical management including treatment has been repeatedly studied. Tumor markers such as CA125, CA19-9, and HE4 and image diagnosis using MRI, CT, PET, etc. are indispensable diagnostic aid tools. In the initial treatment, primary debulking surgery (PDS) is basically effective, but fertility preservation can be considered depending on the case. For advanced cancers, interval debulking surgery (IDS) is considered after several cycles of neoadjuvant chemotherapy (NAC). Although the combination of paclitaxel and carboplatin (TC) regimen was originally established as the standard chemotherapy for ovarian cancer regardless of tissue type, new treatments in clinical trials, including molecular-targeted therapeutic agents, are being investigated. The main treatment for recurrent cancer is chemotherapy, and sensitivity to chemotherapy based on the disease-free interval has been considered in the choice of treatment. Furthermore, in recent years, risk-reducing bilateral salpingo-oophorectomy has been undertaken to prevent the onset of hereditary breast and ovarian cancer. It is also being studied how to manage the follow-up after treatment and hormone replacement.

AB - Ovarian cancer has high morbidity and mortality worldwide, and its mortality is the highest among female genital cancers. Improvement in clinical outcome is an urgent issue for ovarian cancer, and clinical management including treatment has been repeatedly studied. Tumor markers such as CA125, CA19-9, and HE4 and image diagnosis using MRI, CT, PET, etc. are indispensable diagnostic aid tools. In the initial treatment, primary debulking surgery (PDS) is basically effective, but fertility preservation can be considered depending on the case. For advanced cancers, interval debulking surgery (IDS) is considered after several cycles of neoadjuvant chemotherapy (NAC). Although the combination of paclitaxel and carboplatin (TC) regimen was originally established as the standard chemotherapy for ovarian cancer regardless of tissue type, new treatments in clinical trials, including molecular-targeted therapeutic agents, are being investigated. The main treatment for recurrent cancer is chemotherapy, and sensitivity to chemotherapy based on the disease-free interval has been considered in the choice of treatment. Furthermore, in recent years, risk-reducing bilateral salpingo-oophorectomy has been undertaken to prevent the onset of hereditary breast and ovarian cancer. It is also being studied how to manage the follow-up after treatment and hormone replacement.

KW - Adjuvant chemotherapy

KW - Diagnostic imaging

KW - Follow-up after treatment

KW - Hormone replacement therapy

KW - Interval debulking surgery

KW - Molecular-targeted drugs

KW - Neoadjuvant chemotherapy

KW - Primary debulking surgery

KW - Risk-reducing salpingo-oophorectomy

KW - Staging laparotomy

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=85053169337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053169337&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-7941-2_11

DO - 10.1007/978-981-10-7941-2_11

M3 - Chapter

AN - SCOPUS:85053169337

SN - 9789811079405

SP - 135

EP - 151

BT - Cell Biology of the Ovary

PB - Springer Singapore

ER -